Equity · Healthcare
SION
NASDAQSionna Therapeutics (SION)
The line runs 6 USD on 12 August through 5 USD on 2 October, on a scale from 4 to 10. Days the market did not trade hold the previous close, flat.
- Market cap
- 226.1M USD
- EPS, diluted, year to Dec 2025
- −1.88 USD
- Avg volume
- 66.7K
as of Oct 2, 2026
Have Sionna Therapeutics (SION) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Sionna Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 20 Oct 2025, show no open-market purchase.
Form 4, 90 days to 10 Nov 2026, newest reported trade 17 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Sep 2026 | RA CAPITAL MANAGEMENT, L.P.Director | Sell | 3,448,811 | 21.8M USD |
4 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Sep 2026 | Fitzpatrick JenniferCLO and Head of Program Mgmt. | Award | 56,265 | |
| 17 Sep 2026 | McKee CharlotteCMO and Head of R&D | Award | 100,000 | |
| 17 Sep 2026 | Ridloff ElenaCFO and CBO | Award | 94,537 | |
| 17 Sep 2026 | Cloonan MichaelPresident & CEO | Award | 218,050 |
Which funds hold Sionna Therapeutics (SION)?
8 of the 45 institutional funds we track reported a Sionna Therapeutics position for the quarter ended 30 Jun 2026 — a combined 229.0M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Viking Global Investors | Held (±25%) | 3,195,181 | 140.6M USD | |
| Citadel Advisors | Held (±25%) | 1,147,636 | 50.5M USD | −1.7% |
| Baker Bros. Advisors | Held (±25%) | 400,000 | 17.6M USD | |
| Millennium Management | Added | 276,733 | 12.2M USD | +96.8% |
| D. E. Shaw & Co. | New position | 101,644 | 4.5M USD | |
| Point72 Asset Management | Trimmed | 49,328 | 2.2M USD | −63.9% |
| Tudor Investment Corp | New position | 22,575 | 993K USD | |
| Marshall Wace | New position | 12,599 | 554K USD | |
| Two Sigma Investments | Exited |
What has been filed or recorded for Sionna Therapeutics (SION)?
The filings we hold for Sionna Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 05 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,445 shares | 12K USD notional · 0.005% of shares out |
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 271 shares | 1K USD notional · 0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.66 USD | |
| 30 Jun 2026 | Financials | Total assets | 283.2M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 265.8M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.60 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.88 USD | |
| 31 Dec 2025 | Financials | Net income | −75.3M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.88 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.46 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.41 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.62 USD | |
| 31 Dec 2024 | Annual report | FY 2025 reported | EPS −15.99 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2025 reported | EPS −5.67 USD |
What do people ask about Sionna Therapeutics (SION)?
What did Sionna Therapeutics shares close at?5.00
Sionna Therapeutics closed at 5.00 USD on 2 Oct 2026, down 1.67% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Sionna Therapeutics’ market cap?226.1M
Sionna Therapeutics is worth 226.1M USD by market value as of 2 Oct 2026, which is the share price times the shares on issue from its SEC filings.
Have Sionna Therapeutics insiders bought or sold shares recently?1 sale
In the 90 days to 10 Nov 2026, Sionna Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 20 Oct 2025, show no open-market purchase. A further 4 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Sionna Therapeutics?8 of 45
8 of the 45 funds we track reported a Sionna Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Viking Global Investors, Citadel Advisors and Baker Bros. Advisors. See Funds
When did Sionna Therapeutics last report earnings?−0.66
Sionna Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.66 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings